Profil

LECHANTEUR Chantal

Département de médecine interne > Laboratoire de thérapie cellulaire et génique (LTCG)

See author's contact details
Main Referenced Co-authors
Beguin, Yves  (53)
Briquet, Alexandra  (39)
Baudoux, Etienne  (34)
Detry, Olivier  (22)
Baron, Frédéric  (19)
Main Referenced Keywords
mesenchymal stromal cells (7); MSC (6); cell therapy (4); Crohn’s disease (4); Mesenchymal stem cells (4);
Main Referenced Unit & Research Centers
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège [BE] (1)
Giga-Signal Transduction - ULiège [BE] (1)
Main Referenced Disciplines
Hematology (36)
Surgery (19)
Gastroenterology & hepatology (10)
Urology & nephrology (9)
Oncology (6)

Publications (total 67)

The most downloaded
810 downloads
LECHANTEUR, C., Baila, S., Janssen, M. E., GIET, O., BRIQUET, A., BAUDOUX, E., & Beguin, Y. (2014). Large-Scale Clinical Expansion of Mesenchymal Stem Cells in the GMP-Compliant, Closed Automated Quantum® Cell Expansion System: Comparison with Expansion in Traditional T-Flasks. Journal of Stem Cell Research and Therapy, 4 (8), 1000222. doi:10.4172/2157- 7633.1000222 https://hdl.handle.net/2268/172676

The most cited

176 citations (Scopus®)

Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., LEJEUNE, M., Gothot, A., Fillet, G., & Beguin, Y. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16 (6), 838-47. doi:10.1016/j.bbmt.2010.01.011 https://hdl.handle.net/2268/77204

Delgadillo, J., Kerkelä, E., Waters, A., van den Akker, E., LECHANTEUR, C., BAUDOUX, E., Gardiner, N., De Vos, J., & Vives, J. (2023). A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe. Cytotherapy. doi:10.1016/j.jcyt.2023.08.001
Peer Reviewed verified by ORBi

Servais, S., Baron, F., LECHANTEUR, C., Seidel, L., BAUDOUX, E., BRIQUET, A., Selleslag, D., Maertens, J., Poire, X., Schroyens, W., Graux, C., De Becker, A., Zachee, P., Ory, A., Herman, J., Kerre, T., & Beguin, Y. (2023). Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Frontiers in Immunology, 14. doi:10.3389/fimmu.2023.1106464
Peer Reviewed verified by ORBi

Reenaers, C., GILLARD, R., Coimbra, C., GILLARD, R., Meunier, P., LECHANTEUR, C., BAUDOUX, E., BOUTAFFALA, L., Beguin, Y., & Louis, E. (2023). Clinical and MRI evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn’s disease: results from a prospective monocentric study. Journal of Crohn's and Colitis, 17, 728-737. doi:10.1093/ecco-jcc/jjac192
Peer Reviewed verified by ORBi

GREGOIRE, C.* , LAYIOS, N.* , LAMBERMONT, B., LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., THYS, M., Dardenne, N., Misset, B.* , & BEGUIN, Y.*. (04 July 2022). Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Frontiers in Immunology, 13, 932360. doi:10.3389/fimmu.2022.932360
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.
Editorial Reviewed verified by ORBi

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (2022). Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: a phase I-II clinical study. Journal of Crohn's and Colitis, 16, 506-510. doi:10.1093/ecco-jcc/jjab154
Peer Reviewed verified by ORBi

VANDERMEULEN, M., Mohamed-Wais, M., ERPICUM, P., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., MAGGIPINTO, G., Jouret, F., Beguin, Y., & Detry, O. (2022). Infusion of allogeneic mesenchymal stromal cells after liver transplantation: Five-year follow-up. Liver Transplantation, 28, 636-646. doi:10.1002/lt.26323
Peer reviewed

MALAISE, O., PAULISSEN, G.* , DEROYER, C., Cirgea, F., Poulet, C., LECHANTEUR, C., Brondello, J.-M., DE SENY, D., & MALAISE, M. (December 2021). Influence des glucocorticoïdes sur les caractéristiques de la sénescence cellulaire dans les fibroblastes synoviaux d’origine arthrosique. Revue du Rhumatisme, 88 (S1), 157.
Peer reviewed
* These authors have contributed equally to this work.

MALAISE, O.* , PAULISSEN, G.* , DEROYER, C., Ciregia, F., Poulet, C., NEUVILLE, S., PLENER, Z., DANIEL, C., Gillet, P., LECHANTEUR, C., Brondello, J.-M., DE SENY, D.* , & MALAISE, M.*. (16 November 2021). Influence of Glucocorticoids on Cellular Senescence Hallmarks in Osteoarthritic Fibroblast-like Synoviocytes. Journal of Clinical Medicine, 10 (22), 5331. doi:10.3390/jcm10225331
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (October 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. United European Gastroenterology.
Peer reviewed

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., Pariente, B., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & LOUIS, E. (July 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. 16th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2021 Virtual.
Peer reviewed

LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., & BEGUIN, Y. (2021). MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process. Cells, 10, 1320. doi:10.3390/cells10061320
Peer Reviewed verified by ORBi

VANDERMEULEN, M., ERPICUM, P., WEEKERS, L., BRIQUET, A., LECHANTEUR, C., Detry, O., Beguin, Y., & Jouret, F. (May 2020). Mesenchymal Stromal Cells in Solid Organ Transplantation. Transplantation, 104 (5), 923-936. doi:10.1097/TP.0000000000003077
Peer Reviewed verified by ORBi

HAUZEUR, J.-P., LECHANTEUR, C., BAUDOUX, E., De Maertelaer, V., Pather, S., Katz, R., Malaise, M., Ino, J., & Beguin, Y. (2020). Did Osteoblastic Cell Therapy Improve the Prognosis of Prefracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial. Clinical Orthopaedics and Related Research, 478, 1307-1315.
Peer Reviewed verified by ORBi

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619
Peer Reviewed verified by ORBi

ERPICUM, P., WEEKERS, L., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., GREGOIRE, C., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., MAGGIPINTO, G., SOMJA, J., Pottel, H., Baron, F., Jouret, F., & BEGUIN, Y. (2019). Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney International, 95, 693-707. doi:10.1016/j.kint.2018.08.046
Peer Reviewed verified by ORBi

GREGOIRE, C., BRIQUET, A., PIRENNE, C., LECHANTEUR, C., LOUIS, E.* , & BEGUIN, Y.*. (November 2018). Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study. Digestive and Liver Disease, 50 (11), 1251-1255. doi:10.1016/j.dld.2018.08.015
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Servais, S., Baron, F., LECHANTEUR, C., SEIDEL, L., Selleslag, D., Maertens, J., BAUDOUX, E., Zachee, P., Van Gelder, M., Noens, L., Kerre, T., Lewalle, P., Schroyens, W., ORY, A., & Beguin, Y. (2018). Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget, 9 (29), 20590-20604. doi:10.18632/oncotarget.25020
Peer Reviewed verified by ORBi

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., Briquet, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & Beguin, Y. (July 2017). Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. Journal of Hepatology, 67 (1), 47-55. doi:10.1016/j.jhep.2017.03.001
Peer Reviewed verified by ORBi

WEEKERS, L., ERPICUM, P., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (16 March 2017). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up [Paper presentation]. 24th Annual Meeting, Bruxelles, Belgium.

GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc.
Peer reviewed

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & BEGUIN, Y. (January 2017). UNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE. Transplant International, 30 (suppl 1), 8 (O12.
Peer Reviewed verified by ORBi

GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864
Peer Reviewed verified by ORBi

GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc.
Peer reviewed

HAUZEUR, J.-P., Tungouz, M., LECHANTEUR, C., Beguin, Y., BAUDOUX, E., de maertelaer, V., Pather, S., Katz, R., Ino, J., Egrise, D., Malaise, M., & Gangji, V. (October 2016). Ostéoblastes autologues (PREOB®) versus concentré de moelle autologue dans l’ostéonécrose de la tête fémorale : étude randomisée. Revue de Chirurgie Orthopédique et Traumatologie, 102, 73. doi:10.1016/j.rcot.2016.08.002
Peer reviewed

Erpicum, P., WEEKERS, L., DETRY, O., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (28 April 2016). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up [Paper presentation]. Annual Meeting of the BVN-SBN, Bruxelles, Belgium.

Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society.

WEEKERS, L., Erpicum, P., DETRY, O., BONVOISIN, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (2016). administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up. Transplant International, 29 (Suppl 2), 13 -p6.
Peer Reviewed verified by ORBi

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.
Peer Reviewed verified by ORBi

LECHANTEUR, C., BRIQUET, A., GIET, O., DELLOYE, O., BAUDOUX, E., & BEGUIN, Y. (2016). Clinical - scale expansion of mesenchymal stromal cells: a large banking experience. Journal of Translational Medicine, 14, 145-159. doi:10.1186/s12967-016-0892-y
Peer Reviewed verified by ORBi

WEEKERS, L., ERPICUM, P., DETRY, O., JOURET, F., LECHANTEUR, C., DELBOUILLE, M.-H., BRIQUET, A., BAUDOUX, E., & BEGUIN, Y. (November 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. Transplant International, 28 (S4), 223-224/BO278.
Peer Reviewed verified by ORBi

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., HONORE, P., & BEGUIN, Y. (November 2015). Infusion of third-party mesenchymal stem cells after liver transplantation: a phase-1, open-label, clinical study. Transplant International, 28 (S4), 10/O27.
Peer Reviewed verified by ORBi

WEEKERS, L., ERPICUM, P., DETRY, O., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (May 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. American Journal of Transplantation, 15 (suppl 3).
Peer Reviewed verified by ORBi

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (April 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study. Journal of Hepatology, 62 (S2), 311 (P0052.
Peer Reviewed verified by ORBi

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (27 March 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study [Poster presentation]. 22nd Annual Meeting, Brussels, Belgium.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (March 2015). Infusion of third-party mesenchymal stream cells after liver transplantation: a phase-1, open-label, clinical study. Acta Gastro-Enterologica Belgica, 78 (1), 29.
Peer Reviewed verified by ORBi

Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597
Peer Reviewed verified by ORBi

DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56.
Peer reviewed

Hannon, M., LECHANTEUR, C., Lucas, S., Somja, J., Seidel, L., Belle, L., Bruck, F., BAUDOUX, E., GIET, O., Chantillon, A.-M., Delvenne, P., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (17 June 2014). Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion, 54 (February), 353-363. doi:10.1111/trf.12279
Peer Reviewed verified by ORBi

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9
Peer Reviewed verified by ORBi

BRIQUET, A., GREGOIRE, C., Comblain, F., Servais, L., Zeddou, M., LECHANTEUR, C., & Beguin, Y. (2014). Human bone marrow, umbilical cord or liver mesenchymal stromal cells fail to improve liver function in a model of CCl4-induced liver damage in NOD/SCID/IL-2Ry(null) mice. Cytotherapy, 16, 1511-1518. doi:10.1016/j.jcyt.2014.07.003
Peer Reviewed verified by ORBi

LECHANTEUR, C., Baila, S., Janssen, M. E., GIET, O., BRIQUET, A., BAUDOUX, E., & Beguin, Y. (2014). Large-Scale Clinical Expansion of Mesenchymal Stem Cells in the GMP-Compliant, Closed Automated Quantum® Cell Expansion System: Comparison with Expansion in Traditional T-Flasks. Journal of Stem Cell Research and Therapy, 4 (8), 1000222. doi:10.4172/2157- 7633.1000222
Peer Reviewed verified by ORBi

MOERMANS, C., LECHANTEUR, C., BAUDOUX, E., GIET, O., HENKET, M., SEIDEL, L., LEJEUNE, M., WILLEMS, E., Baron, F., LOUIS, R., & BEGUIN, Y. (2014). Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplantation, 98 (3), 348-353. doi:10.1097/TP.0000000000000068
Peer Reviewed verified by ORBi

Erpicum, P., DETRY, O., WEEKERS, L., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2014). Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrology Dialysis Transplantation, 29, 1487-1493. doi:10.1093/ndt/gft538
Peer Reviewed verified by ORBi

VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418
Peer Reviewed verified by ORBi

DETRY, O., DELBOUILLE, M.-H., LECHANTEUR, C., SOMJA, J., DE ROOVER, A., WEEKERS, L., SQUIFFLET, J.-P., Honoré, P., DELVENNE, P., MEURISSE, M., BAUDOUX, E., & BEGUIN, Y. (30 May 2013). INFUSION OF THIRD-PARTY MESENCHYMAL STEM CELLS (MSC) AFTER KIDNEY AND LIVER TRANSPLANTATION: A PHASE I-II, OPEN-LABEL, CLINICAL STUDY (EudraCT 2011-001822-81 & NCT01429038) [Poster presentation]. 13eme rencontre de Beaune, Beaune, France.

Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Hannon, M., LECHANTEUR, C., Somja, J., Lucas, S., Belle, L., Bruck, F., Baudoux, E., Beguin, Y., Humblet-Baron, S., & Baron, F. (2013). Infusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 15.

Hauzeur, J.-P., Bernard, C., Egrise, D., Kurth, W., Van Cauwenberge, H., LECHANTEUR, C., Gillet, P., Beguin, Y., MALAISE, M., & HUSTINX, R. (2013). (111)Indium-oxine labelling for evaluating the homing process of autologous osteoblasts implanted percutaneously in atrophic nonunion fractures. International Orthopaedics, 37 (1), 131-6. doi:10.1007/s00264-012-1719-y
Peer Reviewed verified by ORBi

BRIQUET, A., HALLEUX, A., LECHANTEUR, C., & BEGUIN, Y. (2013). Neuropeptides to replace serum in cryopreservation of mesenchymal stromal cells ? Cytotherapy, 15, 1385-1394. doi:10.1016/j.jcyt.2013.06.012
Peer Reviewed verified by ORBi

DETRY, O., DELBOUILLE, M.-H., LECHANTEUR, C., SOMJA, J., DE ROOVER, A., WEEKERS, L., DELVENNE, P., BAUDOUX, E., & BEGUIN, Y. (19 October 2012). Infusion of third party mesenchymal stem cells (MSC) after kidney and liver transplantation: a phase I-II, open-label, clinical study [Paper presentation]. 4th Expert meeting, Barcelona, Spain.

Bruck, F., de Leval, L., Belle, L., LECHANTEUR, C., Hannon, M., BRIQUET, A., Dubois, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., BEGUIN, Y., & BARON, F. (2012). Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease [Poster presentation]. Belgian Hematological Society General Annual Meeting.

BERNARD, C., HAUZEUR, J.-P., LECHANTEUR, C., VAN CAUWENBERGE, H., BEGUIN, Y., MALAISE, M., KURTH, W., GILLET, P., & HUSTINX, R. (2011). Evaluation of the homing process in the treatment of atrophic nonunion fractures by percutaneous autologous osteoblast cell implantation. Journal of Nuclear Medicine, 52 (SUPPL), 510.
Peer Reviewed verified by ORBi

Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., LEJEUNE, M., Gothot, A., Fillet, G., & Beguin, Y. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16 (6), 838-47. doi:10.1016/j.bbmt.2010.01.011
Peer Reviewed verified by ORBi

Zeddou, M., Briquet, A., Relic, B., Josse, C., Malaise, M., Gothot, A., Lechanteur, C., & Beguin, Y. (2010). The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biology International, 34 (7), 693-701. doi:10.1042/CBI20090414
Peer Reviewed verified by ORBi

Baron, F., WILLEMS, E., LECHANTEUR, C., BAUDOUX, E., Frere, P., Vanbellinghen, J., Bruck, F., Gothot, A., HAFRAOUI, K., Fillet, G., & Beguin, Y. (2009). Co-transplantation of mesenchymal stem cells might mitigate acute GvHD without abrogating graftversus- tumour alloreactivity after allogeneic transplantation with non-myeloablative conditioning [Paper presentation]. 35th EBMT Annual Meeting.

Robe, P., Nguyen-Khac, M.-T., Lambert, F., Lechanteur, C., Jolois, O., Ernst-Gengoux, P., Rogister, B., & Bours, V. (January 2007). Sufasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. International Journal of Oncology, 30 (1), 283-290. doi:10.3892/ijo.30.1.283
Peer Reviewed verified by ORBi

Lechanteur, C., Jacobs, N., Greimers, R., Benoit, V., Deregowski, V., Chariot, A., Merville, M.-P., & Bours, V. (03 March 2005). Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis. Oncogene, 24 (10), 1788-1793. doi:10.1038/sj.onc.1208436
Peer Reviewed verified by ORBi

Lechanteur, C., Delvenne, P., Princen, F., Lopez Y Cadenas, M., Fillet, G., Gielen, J., Merville, M.-P., & Bours, V. (September 2000). Combined Suicide and Cytokine Gene Therapy for Peritoneal Carcinomatosis. Gut, 47 (3), 343-8. doi:10.1136/gut.47.3.343
Peer Reviewed verified by ORBi

Lechanteur, C., Moutschen, M., Princen, F., Lopez, M.-J., Franzen, E., Gielen, J., Bours, V., & Merville, M.-P. (May 2000). Antitumoral Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-12-Expressing Dhd/K12 Colon Adenocarcinoma Cells. Cancer Gene Therapy, 7 (5), 676-82. doi:10.1038/sj.cgt.7700152
Peer Reviewed verified by ORBi

Princen, F., Lechanteur, C., Lopez, M.-J., Gielen, J., Bours, V., & Merville, M.-P. (2000). Similar Efficiency of DNA-Liposome Complexes and Retrovirus-Producing Cells for Hsv-Tk Suicide Gene Therapy of Peritoneal Carcinomatosis. Journal of Drug Targeting, 8 (2), 79-89. doi:10.3109/10611860008996854
Peer Reviewed verified by ORBi

Bentires-Alj, M., Hellin, A.-C., Lechanteur, C., Princen, F., Lopez Y Cadenas, M., Fillet, G., Gielen, J.-L., Merville, M.-P., & Bours, V. (January 2000). Cytosine Deaminase Suicide Gene Therapy for Peritoneal Carcinomatosis. Cancer Gene Therapy, 7 (1), 20-6. doi:10.1038/sj.cgt.7700093
Peer Reviewed verified by ORBi

Princen, F., Robe, P., Lechanteur, C., Mesnil, M., Rigo, J.-M., Gielen, J., Merville, M.-P., & Bours, V. (November 1999). A Cell Type-Specific and Gap Junction-Independent Mechanism for the Herpes Simplex Virus-1 Thymidine Kinase Gene/Ganciclovir-Mediated Bystander Effect. Clinical Cancer Research, 5 (11), 3639-44.
Peer Reviewed verified by ORBi

Princen, F., Lechanteur, C., Lopez Y Cadenas, M., Rocoux, G., Detroz, B., Gielen, J.-L., Fillet, G., Merville, M.-P., & Bours, V. (August 1998). Repeated Cycles of Retrovirus-Mediated Hsvtk Gene Transfer Plus Ganciclovir Increase Survival of Rats with Peritoneal Carcinomatosis. Gene Therapy, 5 (8), 1054-60. doi:10.1038/sj.gt.3300710
Peer Reviewed verified by ORBi

Lechanteur, C., Princen, F., Lo Bue, S., Detroz, B., Fillet, G., Gielen, J., Bours, V., & Merville, M.-P. (1998). Hsv-1 Thymidine Kinase Gene Therapy for Peritoneal Carcinomatosis. Advances in Experimental Medicine and Biology, 451, 115-9. doi:10.1007/978-1-4615-5357-1_18
Peer Reviewed verified by ORBi

Lechanteur, C., Princen, F., Lo Bue, S., Detroz, B., Fillet, G., Gielen, J.-L., Bours, V., & Merville, M.-P. (November 1997). Hsv-1 Thymidine Kinase Gene Therapy for Colorectal Adenocarcinoma-Derived Peritoneal Carcinomatosis. Gene Therapy, 4 (11), 1189-94. doi:10.1038/sj.gt.3300520
Peer Reviewed verified by ORBi

Charlier, C., Bruyneel, E., Lechanteur, C., Bracke, M., Mareel, M., & Castronovo, V. (19 December 1996). Enhancement of Tamoxifen-Induced E-Cadherin Function by Ca2+ Channel Antagonists in Human Breast Cancer Mcf7/6 Cells. European Journal of Pharmacology, 317 (2-3), 413-6. doi:10.1016/S0014-2999(96)00816-3
Peer Reviewed verified by ORBi

Contact ORBi